[go: up one dir, main page]

CA2251733A1 - Therapie associee reposant sur l'utilisation de la dehydroepiandrosterone (dhea) - Google Patents

Therapie associee reposant sur l'utilisation de la dehydroepiandrosterone (dhea) Download PDF

Info

Publication number
CA2251733A1
CA2251733A1 CA002251733A CA2251733A CA2251733A1 CA 2251733 A1 CA2251733 A1 CA 2251733A1 CA 002251733 A CA002251733 A CA 002251733A CA 2251733 A CA2251733 A CA 2251733A CA 2251733 A1 CA2251733 A1 CA 2251733A1
Authority
CA
Canada
Prior art keywords
interleukin
patient
group
treatment
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002251733A
Other languages
English (en)
Inventor
Patrick T. Prendergast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2251733A1 publication Critical patent/CA2251733A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention a trait à des médicaments, à leurs procédés de production ainsi qu'à des nécessaires comprenant, (1), un composé de 17-cétostéroïde et/ou (2), un antisérum, polyclonal ou monoclonal, dirigé contre l'interleukine 10, l'interleukine 2 ou l'interleukine 12, ou en combinaison, soit avec n'importe quel composé en mesure d'inhiber réellement une synthèse ou la fonction biologique de l'interleukine 10, de l'interleukine 12 ou de l'interleukine 2, soit avec un agent bloquant de molécule réceptrice de l'interleukine 10, de l'interleukine 12 ou de l'interleukine 2, soit avec un antisérum, qu'il soit polyclonal ou monoclonal, dirigé contre l'alpha-foetoprotéine. Cette invention se rapporte également à des méthodes thérapeutiques faisant intervenir ces composés ou des combinaisons de ces composés, à des méthodes renforçant notamment une réponse immunitaire de protection de Th¿1? par l'utilisation du composé de 17-cétostéroïde en tant qu'agent antiviral, antibactérien, anti-mycoplasme ou en tant qu'agent antiparasite intracellulaire. L'invention a, en outre, trait à des traitements concernant divers composés et leurs combinaisons.
CA002251733A 1996-04-17 1997-04-17 Therapie associee reposant sur l'utilisation de la dehydroepiandrosterone (dhea) Abandoned CA2251733A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1569596P 1996-04-17 1996-04-17
US60/015,695 1996-04-17

Publications (1)

Publication Number Publication Date
CA2251733A1 true CA2251733A1 (fr) 1997-10-23

Family

ID=21773003

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251733A Abandoned CA2251733A1 (fr) 1996-04-17 1997-04-17 Therapie associee reposant sur l'utilisation de la dehydroepiandrosterone (dhea)

Country Status (9)

Country Link
EP (1) EP0901375A1 (fr)
JP (1) JP2000508654A (fr)
KR (1) KR20000005539A (fr)
CN (1) CN1216470A (fr)
AU (1) AU734807B2 (fr)
CA (1) CA2251733A1 (fr)
IL (1) IL126623A0 (fr)
NO (1) NO984851L (fr)
WO (1) WO1997038695A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775614B2 (en) * 1998-11-24 2004-08-05 Harbor Biosciences, Inc. Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other togaviruses
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
CA2356539A1 (fr) * 1998-11-24 2000-06-08 Hollis-Eden Pharmaceuticals, Inc. Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du paludisme et le traitement de la trypanosiomase africaine ou americaine
WO2000032176A2 (fr) * 1998-11-27 2000-06-08 Hollis-Eden Pharmaceuticals, Inc. Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement de la toxoplasmose ou de la cryptosporidiose
EP2983705A2 (fr) * 2013-04-10 2016-02-17 Skau Aps Utilisation de peptides immunosuppresseurs en tant qu'adjuvants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
US5231012A (en) * 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
AU680628B2 (en) * 1992-08-20 1997-08-07 Schering Corporation Novel uses of IL-4 and/or IL-10, and antibodies against the same
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases

Also Published As

Publication number Publication date
IL126623A0 (en) 1999-08-17
NO984851D0 (no) 1998-10-16
KR20000005539A (ko) 2000-01-25
CN1216470A (zh) 1999-05-12
AU2574197A (en) 1997-11-07
JP2000508654A (ja) 2000-07-11
AU734807B2 (en) 2001-06-21
NO984851L (no) 1998-12-17
WO1997038695A1 (fr) 1997-10-23
EP0901375A1 (fr) 1999-03-17

Similar Documents

Publication Publication Date Title
FI87733C (fi) Foerfarande foer modulering av djurcellers reaktioner in vitro med preparat innehaollande 8-substituerade guaninderivat
US10765723B2 (en) Use of low dose IL-2 for treating autoimmune—related or inflammatory disorders
Chandran et al. Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial
Slade et al. Prednisone-induced alterations of circulating human lymphocyte subsets
JP2023029565A (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ－２の使用
JPH06172183A (ja) 医薬組成物
Goodwin et al. Effect of physical stress on sensitivity of lymphocytes to inhibition by prostaglandin E2.
JPH0586378B2 (fr)
Campbell et al. Immunosuppression in the treatment of inflammatory bowel disease. I. Changes in lymphoid sub-populations in the blood and rectal mucosa following cessation of treatment with azathioprine
Hohlfeld et al. Therapies
Imami et al. Induction of HIV‐1‐specific T cell responses by administration of cytokines in late‐stage patients receiving highly active anti‐retroviral therapy
Morikawa et al. Immunomodulatory effect of fosfomycin on human B-lymphocyte function
Hirsch Defective autologous mixed lymphocyte reactivity in multiple sclerosis
AU734807B2 (en) Dhea combination therapy
WO1998047516A1 (fr) Therapie combinee mettant en application des 17-cetosteroides et des inhibiteurs d'interleukine, ou interleukine-10 eventuellement avec des inhibiteurs d'interleukine
Polmar Enzyme replacement and other biochemical approaches to the therapy of adenosine deaminase deficiency
CA2255856C (fr) Utilisations therapeutiques d'un compose d'aminosterol
Stavinoha et al. Current therapy of chronic liver disease
Afzelius et al. The serotonin analogue buspirone increases the function of PBMC from HIV-infected individuals in vitro
CN112656801A (zh) 孕激素在治疗细胞因子释放综合征中的应用
Lear et al. Restoration of allograft responsiveness in B rats
JPH01172345A (ja) 移植片対宿主病を防ぐための薬剤キット
Bartlett et al. Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042
EP0372541A1 (fr) Procédé pour impartir l'immunosupression
Andrade‐Mena et al. Effects of carbamazepine on murine humoral and cellular immune responses

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued